




SEATTLE, Wash.
December 5, 2018

In-vivo studies have been conducted in human volunteers at Know Labs that successfully demonstrated continuous measurement of blood glucose as well as acetaminophen and ethyl alcohol. As its highest priority, we are focused on blood glucose monitoring that we will show below in detail.

Know Labs, Inc. has developed a truly non-invasive continuous glucose monitor with no needles, filaments, or microneedles. It uses proprietary technologies capable of uniquely identifying glucose using radio frequency spectroscopy, delivered and received by specially designed antennas and analyzed with unique algorithms which concentrate on the measured patterns of absorption at predefined frequencies. This significantly increases the ability to both identify the unique digital 'signature' of the molecule and quantify specific molecules of interest such as glucose.

Volunteers without diabetes who were fasting at study start were connected to the Know Labs noninvasive UBAND™ BioRFID™ device and a “minimally invasive” FreeStyle Libre™. After 30 minutes they drank an oral glucose solution. One hundred eighty (180) paired readings were collected over 3 hours, demonstrating 100% of pairs inside the no risk ‘green’ zone of the Surveillance Error Grid (SEG-the standard tool for measuring clinical accuracy of blood glucose monitors). The range of glucose values in these first studies (using the FreeStyle Libre as the reference glucose) was 86 to 202 mg/dL (4.8 – 11.2 mmol/L).

There was a 4.3% mean difference in UBAND glucose values compared to the FreeStyle Libre (range -16.1 to 17.4 with 75% of differences less than 5.0%). 97% of UBAND CGM readings were within 15% of the FreeStyle reading and 100% were within 20%.



UBAND vs FreeStyle Libre

The UBAND glucose is the measured glucose (y axis) and the FreeStyle Libre is the reference glucose (x axis).

This clearly demonstrates that accurate, non-invasive continuous glucose monitoring in patients is an achievable goal.

About Know Labs, Inc.

[Know Labs, Inc.](#) is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses [spectroscopy](#) to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a continuous glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2020, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.